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ABSTRACT 
Previous molecular dynamic simulations have reported elongation of the 
existing β-sheet in prion proteins. Detailed examination has shown that these 
elongations do not extend beyond the proline residues flanking these β-sheets. In 
addition, proline has also been suggested to possess a possible structural role in 
preserving protein interaction sites by preventing invasion of neighbouring secondary 
structures. In this paper, we have studied the possible structural role of the flanling 
proline residues by simulating mutant structures with alternate substitution of the 
proline residues with valine. Simulations showed a directional inhibition of elongation 
with the elongation progressing in the direction of valine including evident inhibition 
of elongation by existing proline residues. This suggests that the flanking proline 
residues in prion proteins may have a containment role and would confine the β-sheet 
within a specific length. 
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INTRODUCTION 
Prions are a transmissible agent consisting of an abnormal isoform of the prion 
protein (PrP), designated PrPSC (1). PrPSC (SC for scrapie) is derived from a post-
translational conformational transformation (2,3) of the cellular isoform, PrPC (C for 
cellular) (4,5). The term ‘Prion’ is a dyslexic acronym (6) coined by Prusiner for 
‘Proteinaceous Infectious Particle’ to define a small proteinaceous infectious particle 
that resists inactivation by procedures which modify nucleic acids (7).  According to 
the ‘protein only’ hypothesis, prion propagation involves a novel concept of 
transmission by proteinaceous material alone which is able to convert other normal 
isoforms to itself in an auto catalytic manner causing infection and disease 
proliferation without the transmission of a nucleic acid genome. Prion protein is 
unique in that it goes against two main dogmas in molecular biology. First, prion 
protein has shown that pathogens are able to replicate in the absence of nucleic acids. 
Secondly, prion protein defies the ‘one sequence, one conformation’ dogma because 
the conformation of the normal PrP sequence can transform into a different 
pathogenic conformation, either spontaneously or by association with pre-existing 
pathogenic material. (8). Prion diseases or transmissible spongiform encephalopathies 
(TSE) are characterised by spongiform degeneration and the accumulation of PrPSC 
in the brain. Prion diseases can also been grouped under the more general term of 
conformational diseases such as α1-antitrypsin deficiency, sickle cell anaemia and 
familial amyloid polyneuropathy as all these diseases have comparable inherent 
conformational instability of a specific protein that results in its deposition in the 
tissue of the affected organism. (9,10).   
There are fifteen proline residues in the human prion protein structure with 
twelve residues in the flexible N terminus. The twelve proline residues in the N 
terminus are periodic and conformationally stabilised by copper (11). The other three 
proline residues are located within the globular domain of PrPC. The anti- parallel β-
sheet consisting of strand S2 is flanked at both ends by Pro158 and Pro165 with the 
opposing strand S1 flanked by a single proline at position 137 (Figure 1).  Proline is 
an imino acid that has a pyrrolidine ring structure that prevents participation in the 
usual hydrogen bonding between NH and CO groups of other amino acids. The 
presence of the ring causes proline to be disfavoured in β-sheet structure as its φ angle 
is incompatible and it lacks one potential H-bond donor (12). Consequently, this 
makes its occurrence in β-sheet rare. In fact, the rare occurrences of proline in 
secondary structure have led to the practice of systematically substituting proline in 
mutagenesis studies, thus becoming a practical tool to identify segments involved in 
protein aggregation (13).  proline residues are more frequently found in sharp turns 
linking β-strands (β bends), kinks in transmembrane α-helices, at the edges of β-sheets 
or most frequently, within loops and disordered regions of proteins (13).  
Previously, we have performed MD simulations at denaturing temperatures and 
residual structures showed evidence that suggested that the elongation of S1 and S2 in 
the prion protein is restricted and did not proceed beyond Pro158 and Pro165 flanking 
both sides of S2 and beyond proline137 on the C terminal end of S1 (14). Other MD 
simulations have also shown similar restrictions(15-18) even at elevated temperatures 
(19). The zipper-like progression of sheet formation could therefore be prevented by 
the presence of these proline ‘brackets’. 
A study has also shown that proline is the residue most commonly found in the 
flanking segments of protein–protein interaction sites (20). Examination of over 1600 
protein-protein interaction sites indicated that proline residues are commonly found 
within these flanking segments and the probability of occurrence in flanking segments 
is 2.5 times greater than elsewhere in the structure (20) . As a result, proline ‘brackets’ 
have been proposed to perform a structural role in protecting the conformation and 
integrity of the interaction site by blocking the “invasion” of neighbouring secondary 
structures. (20). Investigation of the properties of proline delimited regions has also 
led to the discovery of the L-Type Ca2+ channel binding site of calciseptine (21). 
Presence of proline residues at the edge of β-sheet has also been proposed as a 
negative design feature to avoid aggregation and essentially serve as a capping 
mechanism (22). A survey of all the prion structures available in PDB revealed that 
proline ‘bracket’ is present and that the secondary structure architecture of the S2 
strand is highly conserved in the different species, as expected from the high degree of 
sequence identity (Table 1). 
This paper follows on from our earlier observations regarding the expansion of 
β-sheet (14) and examines if the existence of proline residues flanking β-strands S1 
and S2 has a role in restraining the zippering process of the β-strands, therefore 
maintaining its length to a fixed number of residues. Variants with alternating proline 
substitutions have been used to examine if specific proline residue plays a distinct role 
in restraining the β-sheet. 
MATERIALS AND METHODS 
The starting structure for all the simulations was based on NMR structure of 
human prion protein domain in PDB designated 1QLX (23), which contains the C 
terminal globular structure of human prion consisting of residues 125-228. The 
structure 1QLX was used as wildtype and the variant structures were constructed 
using Deep View (24) by alternate substitution of  proline with Val at position 135, 
158 and 165 (Figure 1), creating seven mutant variants which were used for the 
simulations (Table 2).  
 The remainder of the structure is left unaltered. The disulphide bond between 
H2 and H3 was left intact as previous work showed that it remains oxidised in PrPSC 
and necessary for infectivity (25,26). All models were solvated in a box of explicit 
Simple Point Charge (SPC) water molecules and simulated using periodic boundary 
conditions (PBC) and particle mesh Ewald (PME) summation that have been shown 
to improved electrostatic interactions (27). Structures were minimised using 200 steps 
of the steepest descent method. Simulations were performed using GROMACS 3.1.4 
package and the all-hydrogen function GROMOS96 (28). Simulations were carried 
out at 300 K and 500 K and isotropic pressure coupling was applied. All systems were 
equilibrated for 200 ps of solute position restrained molecular dynamics (MD). 
Unrestrained MD were performed on all variants for 2 ns with a LINCS algorithm 2 fs 
time step for each system. Simulations that showed a significant increase in β-sheet 
structure were repeated over a longer 10ns time-scale. Simulations were performed at 
pH 7. All the resulting trajectories were analysed using GROMACS utilities. The Cα 
root mean square deviations (RMSD) and Cα root mean square fluctuations (RMSF) 
relative to the average MD structure were calculated. The DSSP  program was used to 
determine the percentage of secondary structure throughout the simulations(29). 
protein structure images were created using PyMOL (30)  and protein Explorer (31). 
RESULTS AND DISCUSSION 
Structural deviations and fluctuations 
Figure 2 shows the RMSD from the NMR structure as a function of simulation 
time for the Cα atom in each variant. Figure 3 shows the RMSF from the NMR 
structure a function of residue number for the Cα atom in each variant. The MD 
simulation showed that all variants were stable throughout the simulation. The Cα 
RMSD values for all eight variants increased during the first 0.1 ns before reaching a 
plateau at 0.15 ns – 0.3 ns (Figure 2). The RMSF of all variants showed that highest 
fluctuations occurred in the N terminus and the loop between helices (H2 and 
H3)(Figure 3) while the globular domain containing H2 and H3 remains relatively 
stable.  Consequently, this created the groove pattern observed in reported MD 
simulations (14,17,19,32,33). The absence of rigid constraints imposed by proline 
residues on the N–Cα rotation in mutated structures did not substantially increase the 
fluctuations of the global conformation. 
β-Sheet content 
Figure 4 a-h shows number of residues forming β-sheets as a function of 
simulation time determined with DSSP. Only two variants VVV (Figure 4a) and PVV 
(Figure 4c) exhibited an increase in the number of residues participating in the β-sheet 
formation. MD simulation of VVV showed a discernible pair-like addition of two 
residues at a time at 0.5 ns and 1.6 ns (Figure 4a), suggesting a zippering process (34). 
A 2-residue extension occurred with the addition of four participating residues at the 
end of the simulation. MD simulation of PVV showed similar but faster pair-like 
increase during the first 0.2 ns. However, the extension in PVV exhibited higher 
fluctuations than VVV. The rest of the variants did not show a sustained increase in 
residue number and only showed fluctuations at around six residues (Figure 4b, d-h). 
The wildtype structure PPP showed the biggest fluctuations in β-sheet content the 
ranging between 0 to 7 residues (Figure 4g). 
Structural evolutions: Elongation of existing β-sheets 
Figure 5 a-d and Figure 6 a-d show the evolution of the secondary structures 
during the MD simulation as determined by DSSP . In all the simulations, the increase 
of β-sheets occurred through the extension of existing secondary structure and not by 
creation of new β-structures anywhere else in the protein structure.  
Analysis of the secondary structure evolution revealed several interesting 
observations. The presence of the Pro158 and Pro165 flanking S2 seems to hinder the 
elongation of β-sheet S1 and S2 and its removal seems to induce β-sheet elongation. 
In VVV and PVV where these two proline residues have been replaced, the 
elongation occurred in both directions. In other variants, the expansion occurs away 
from an existing proline residue, thus creating a directional pattern (Figure 7). The 
presence of proline137 residue did not prevent sheet elongation.  This is probably 
because proline137 is three residues further down the sequence and elongation may 
therefore occur on a longer timescale. Previous MD simulations have reported 
elongation of S1 and S2 (15,16,18,35-37) where all elongation of S2 was limited to 
within the six residues between proline158 and proline165. 
 
Mechanism of elongation 
The MD simulation trajectories for VVV, PVV and PPP were examined by 
superimposing sequential coordinate snapshots of structures to examine its 
conformational changes. The trajectory of VVV showed low fluctuations about the 
secondary structure and did not exhibit any major departure from the NMR structure. 
The reduced mobility of the residues Leu125-Gly126-Gly127-Tyr128 of the N 
terminus is evident by its movement into the globular structure as the zippering 
process realigns it to elongate the β-sheet. The fluctuations are constrained by the 
alignment process of the N terminus which results in the low RMSF range of 0.1-0.25 
nm. In contrast, the Leu125-Gly127-Gly127-Tyr128 residues of PPP exhibited higher 
mobility due to the absence of the zippering and realignment process in VVV, as 
exemplified by the higher RMSF range of 0.1 – 0.5 nm. The trajectory of PVV 
exhibits intermediate behaviour with partial zippering and alignment. The Leu125-
Gly126-Gly127-Tyr128 residues also showed reduced fluctuations compared to PPP. 
In contrast to the N terminus, residues forming segments between S1 and S2 that 
include H1 showed higher mobility in VVV compared to PPP and PVV. These 
increased fluctuations could be attributed to the absence of rigidity that Pro137 
residues imposed on the N–Cα rotation, consequently limiting the plasticity of the 
same segment in PVV and PPP. The global stability of the structure and realignment 
of the N terminus suggest that the elongation of β-sheet occurs through the ability of 
valine to form hydrogen bonding after substituting proline, thus allowing the 
zippering process to continue. 
Extended simulations 
Extended MD simulations were performed to examine structural stability over a 
longer simulation period. Three variants; VVV, PVV, PPP and chicken prion 1U3M 
were simulated. VVV and PVV were selected as both showed an extended zippering 
of the β-sheet compared to the other variants while PPP is selected as a control 
representing the wildtype structure. 1U3M was chosen as the chicken prion 
structure(38) has a different proline trimer sequence at position 151-165-176 with 
approximately 30% sequence identity and is expected to show a different 
conformational behaviour. 
Figure 8a-d shows the evolution of the secondary structures and Figure 9a-d 
shows the β-sheets content of each variant is shown in as determined by DSSP for (a) 
PVV, (b) PPP, (c) 1U5L and (d) VVV respectively. The result for PVV, PPP and 
VVV is similar to their initial runs where the increase of β-sheets occurred through 
the extension of existing secondary structure and not by creation of new β-structures 
anywhere else in the protein structure. The simulation is also stable without any 
changes in the overall protein conformation. The Cα RMSD values for all three 
variants stabilised after 0.3 ns and the Cα RMSF of all variants showed similar groove 
pattern signature observed in the 2ns MD simulation and to other reported MD 
simulations (14,17,19,32,33). The PVV variant showed a 100% increase in the 
number of residues participating in the β-sheet elongation to 13 residues similar to the 
initial 2ns MD simulation (Figure 9a). The longer simulation showed the β-sheet 
formation stabilising 4.4 ns and showed similar elongation mechanism to the earlier 
MD. The VVV variant also showed similar behaviour to the initial MD but with a 
higher degree of structural fluctuation in residues forming segments between S1 and 
S2 that include H1 compared to PVV. These larger fluctuations are exemplified by the 
failure to recruit adjacent residues to extend the β-sheet thus limiting the residue 
participation to 8 amino acids (Figure 9d). In addition, the PPP variant also behaved 
in a similar manner to the initial MD simulation with the number of participating 
residues limited to between 6 and 9 (Figure 9b). The chicken prion also showed 
similar global conformational behaviour with the other 3 variants (Figure 8c). The 
secondary structures were maintained throughout the MD simulation but with larger 
fluctuations. The β-sheet content fluctuated throughout the simulation with the 
number of residues forming β-sheets fluctuating between 8 and 10 residues, similar to 
the ranges showed by VVV (Figure 9c). There was a temporary increase in the 
number of residues participating in β-sheet formation between 1 ns and 2 ns via the 
formation of a turn at the N terminal and creation an unstable triple stranded β-sheets 
(Figure 8c).  
 
CONCLUSIONS 
MD simulation of proline substituted structures showed that removal of proline 
residues induces directional elongation of β-sheet. The extended 10ns MD simulations 
have also shown that the β-sheet structure is stable for certain variant (PVV) but not 
VVV. This suggests that substituting all of the proline residues would reduce 
structural rigidity and increase fluctuations, therefore decreasing the propensity for 
adjacent strands to align and form β-sheets. It also showed that the wildtype variant 
(PPP) did not increase the β-sheet content at the end of the simulation. Simulation of 
the chicken prion did not show an increase even though there were the proline bracket 
were further apart than the human prion, suggesting other factors might contribute to 
the failure of the β-sheet to expand. This is not surprising as the low sequence identity 
with human prion protein might provide altered dynamics compared to mammalian 
derived prion proteins. Further work need to be done to study the molecular dynamics 
signature of chicken as well as other non-mammalian prion such as turtle and frogs 
(38). 
The elongation occurred via a zippering process that is discernible by a pairing 
pattern caused by sequential recruitment of residues in pairs. Therefore, when the 
zipper-like process is halted by the flanking proline in the structure, this suggests that 
proline residues acts as a steric barrier by restricting the number of residues to six 
within the proline ‘bracket’ of proline158 and proline165. Interestingly, the six-
residue length is near the intrinsic limit of conformational stability in anti-parallel β-
sheet. Studies have shown that at least for some anti-parallel sequences, the 
conformational stability increases with strand length to a maximum of seven residues 
(39). The proline ‘bracket’ has also been shown to confine the secondary structures 
within it boundary even in elevated temperature. In contrast, the lone proline at 
residue 137 does not play a role in this ‘bracket’ but seems to contribute only to the 
structural rigidity of the segment between S1 and S2. If the presence of the proline 
‘brackets’ is instrumental in determining and maintaining the length of the β-sheet to 
a fixed number of residues, there is a possibility that the length of additional β-sheet 
propagated by the residues 90-124 of the flexible N terminus (17) must not exceed a 
certain length of the seed strand (S2). Models of possible prion protofibrils created 
using electron crystallography data showed preservation of β-sheet length within the 
proline ‘bracket’, thus reinforcing its possible role in determining β-sheet length 
(40,41). Analysis of sequence evolutionary conservation in 27 mammalian and 9 
avian PrPC has shown that the proline ‘ bracket’ segment PNQVYYRP is highly 
conserved (42). In addition, the segment XPNXVY that contains proline158 has a 
higher than average sequence conservation and appear to be needed for the stability of 
the "PrP-fold" (38).  Experimentally, studies have shown that the existence of proline 
residues plays a significant role in protein conformational stability (43,44) and 
function (45). However, this unique role is attributed to the limited conformation that 
proline residues confer to the N–Cα rotation and not because of its inability to form β-
sheet hydrogen bonding. In addition, this is the first time MD simulations have shown 
the role of proline in maintaining the secondary structure in such a manner. 
Nevertheless, further work needs to be done by conducting a survey of existing 
protein structures to examine if this phenomena applies to other similarly structured 
proteins. 
REFERENCES 
 
1.     Prusiner, S. B. 1991. Molecular Biology of prion Diseases. Science 252:1515-
1522. 
 
2.     Pan, K. M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. 
Mehlhorn, Z. W. Huang, R. J. Fletterick, F. E. Cohen, and S. B. Prusiner. 
1993. Conversion of Alpha-Helices into Beta-Sheets Features in the Formation 
of the Scrapie Prion proteins. Proceedings of the National Academy of 
Sciences of the United States of America 90:10962-10966. 
 
3.     Gasset, M., M. A. Baldwin, R. J. Fletterick, and S. B. Prusiner. 1993. 
Perturbation of the Secondary Structure of the Scrapie Prion protein under 
Conditions That Alter Infectivity. Proceedings of the National Academy of 
Sciences of the United States of America 90:1-5. 
 
4.     Borchelt, D. R., M. Scott, A. Taraboulos, N. Stahl, and S. B. Prusiner. 1990. 
Scrapie and Cellular Prion proteins Differ in Their Kinetics of Synthesis and 
Topology in Cultured-Cells. Journal of Neuropathology and Experimental 
Neurology 49:311-311. 
 
5.     Caughey, B., K. Neary, R. Buller, D. Ernst, L. L. Perry, B. Chesebro, and R. E. 
Race. 1990. Normal and Scrapie-Associated Forms of Prion protein Differ in 
Their Sensitivities to Phospholipase and proteases in Intact Neuroblastoma-
Cells. Journal of Virology 64:1093-1101. 
 
6.     Brown, P. and L. Cervenakova. 2005. A prion lexicon (out of control). Lancet 
365:122. 
 
7.     Prusiner, S. B., N. Stahl, and S. J. Dearmond. 1988. Novel Mechanisms of 
Degeneration of the Central Nervous-System - Prion Structure and Biology. 
Ciba Foundation Symposia 135:239-260. 
 
8.     Downing, D. T. and N. D. Lazo. 1999. Molecular modelling indicates that the 
pathological conformations of prion proteins might be beta-helical. 
Biochemical Journal 343:453-460. 
 
9.     Carrell, R. W. and D. A. Lomas. 1997. Conformational disease. The Lancet 
350:134-138. 
 
10.     Kopito, R. R. and D. Ron. 2000. Conformational diseases. Nature Cell Biology 
2:208-209. 
 
11.     Clarke, A. R., G. S. Jackson, and J. Collinge. 2001. The molecular biology of 
prion propagation. Philosophical Transactions of the Royal Society of London 
Series B-Biological Sciences 356:185-194. 
 
12.     Li, S. C., N. K. Goto, K. A. Williams, and C. M. Deber. 1996. alpha-Helical, 
but not beta-sheet, propensity of proline is determined by peptide 
environment. Proceedings of the National Academy of Sciences of the United 
States of America 93:6676-6681. 
 
13.     Reiersen, H. and A. R. Rees. 2001. The hunchback and its neighbours: proline 
as an environmental modulator. Trends in Biochemical Sciences 26:679-684. 
 
14.     Shamsir, M. S. and A. R. Dalby. 2005. One Gene, Two Diseases and Three 
Conformations: Molecular Dynamics Simulations of Mutants of Human Prion 
protein at Room Temperature and Elevated Temperatures. proteins: Structure, 
Function, and Genetics 59:275-290. 
 
15.     DeMarco, M. L. and V. Daggett. 2004. From conversion to aggregation: 
protofibril formation of the prion protein. Proceedings of the National 
Academy of Sciences of the United States of America 101:2293-2298. 
 
16.     Barducci, A., R. Chelli, P. Procacci, and V. Schettino. 2004. Misfolding 
pathways of the prion protein probed by molecular dynamics simulations. 
Biophys. J.:biophysj.104.049882. 
 
17.     Alonso, D. O. V., S. J. DeArmond, F. E. Cohen, and V. Daggett. 2001. 
Mapping the early steps in the pH-induced conformational conversion of the 
prion protein.  Proceedings of the National Academy of Sciences of the United 
States of America  98:2985-2989. 
 
18.     Sekijima, M., C. Motono, S. Yamasaki, K. Kaneko, and Y. Akiyama. 2003. 
Molecular dynamics simulation of dimeric and monomeric forms of human 
prion protein: Insight into dynamics and properties. Biophysical Journal 
85:1176-1185. 
 
19.     Gu, W., T. T. Wang, J. Zhu, Y. Y. Shi, and H. Y. Liu. 2003. Molecular 
dynamics simulation of the unfolding of the human prion protein domain 
under low pH and high temperature conditions. Biophysical Chemistry 
104:79-94. 
 
20.     Kini, R. M. and H. J. Evans. 1995. A Hypothetical Structural Role for proline 
Residues in the Flanking Segments of protein-protein Interaction Sites. 
Biochemical and Biophysical Research Communications 212:1115-1124. 
 
21.     Kini, R. M., R. A. Caldwell, Q. Y. Wu, C. M. Baumgarten, J. J. Feher, and H. J. 
Evans. 1998. Flanking proline Residues Identify the L-Type Ca2+ Channel 
Binding Site of Calciseptine and FS2. Biochemistry 37:9058-9063. 
 
22.     Richardson, J. S. and D. C. Richardson. 2002. Natural beta -sheet proteins use 
negative design to avoid edge-to-edge aggregation.  Proceedings of the 
National Academy of Sciences of the United States of America  99:2754-
2759. 
 
23.     Zahn, R., A. Liu, T. Luhrs, R. Riek, C. von Schroetter, F. Lopez Garcia, M. 
Billeter, L. Calzolai, G. Wider, and K. Wuthrich. 2000. NMR solution 
structure of the human prion protein.  Proceedings of the National Academy of 
Sciences of the United States of America  97:145-150. 
 
24.     Guex, N. and M. C. Peitsch. 1997. SWISS-MODEL and the Swiss-PdbViewer: 
An environment for comparative protein modeling. Electrophoresis 18:2714-
2723. 
 
25.     Turk, E., D. B. Teplow, L. E. Hood, and S. B. Prusiner. 1988. Purification and 
properties of the Cellular and Scrapie Hamster Prion proteins. European 
Journal of Biochemistry 176:21-30. 
 
26.     Herrmann, L. M. and B. Caughey. 1998. The importance of the disulfide bond 
in prion protein conversion. Neuroreport 9:2457-2461. 
 
27.     Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald: An N·log(N) 
method for Ewald sums in large systems. The Journal of Chemical Physics 
98:10089-10092. 
 
28.     Lindahl, E., B. Hess, and D. van der Spoel. 2001. GROMACS 3.0: a package 
for molecular simulation and trajectory analysis. Journal of Molecular 
Modeling 7:306-317. 
 
29.     Kabsch, W. and C. Sander. 1983. Dictionary of protein Secondary Structure - 
Pattern-Recognition of Hydrogen-Bonded and Geometrical Features. 
Biopolymers 22:2577-2637. 
 
30.     Delano, W. L. 2002. The PyMOL Molecular Graphics System. 
 
31.     Martz, E. 2002. protein Explorer: easy yet powerful macromolecular 
visualization. Trends in Biochemical Sciences 27:107-109. 
 
32.     Guilbert, C., F. Ricard, and J. C. Smith. 2000. Dynamic simulation of the 
mouse prion protein. Biopolymers 54:406-415. 
 
33.     Parchment, O. G. and J. W. Essex. 2000. Molecular dynamics of mouse and 
Syrian hamster PrP: Implications for activity. Proteins: Structure, Function, 
and Genetics 38:327-340. 
 
34.     Munoz, V., P. A. Thompson, J. Hofrichter, and W. A. Eaton. 1997. Folding 
dynamics and mechanism of [beta]-hairpin formation. Nature 390:196-199. 
 
35.     De Simone, A., G. G. Dodson, C. S. Verma, A. Zagari, and F. Fraternali. 2005. 
Prion and water: Tight and dynamical hydration sites have a key role in 
structural stability.  Proceedings of the National Academy of Sciences of the 
United States of America  102:7535-7540. 
 
36.     Langella, E., R. Improta, and V. Barone. 2004. Checking the pH-Induced 
Conformational Transition of Prion protein by Molecular Dynamics 
Simulations: Effect of protonation of Histidine Residues. Biophys. J. 87:3623-
3632. 
 
37.     Gsponer, J., P. Ferrara, and A. Caflisch. 2001. Flexibility of the murine prion 
protein and its Asp178Asn mutant investigated by molecular dynamics 
simulations. Journal of Molecular Graphics & Modelling 20:169-182. 
 
38.     Calzolai, L., D. A. Lysek, D. R. Perez, P. Guntert, and K. Wuthrich. 2005. 
Prion protein NMR structures of chickens, turtles, and frogs.  Proceedings of 
the National Academy of Sciences of the United States of America  102:651-
655. 
 
39.     Stanger, H. E., F. A. Syud, J. F. Espinosa, I. Giriat, T. Muir, and S. H. Gellman. 
2001. Length-dependent stability and strand length limits in antiparallel beta -
sheet secondary structure.  Proceedings of the National Academy of Sciences 
of the United States of America  98:12015-12020. 
 
40.     Govaerts, C., H. Wille, S. B. Prusiner, and F. E. Cohen. 2004. Evidence for 
assembly of prions with left-handed {beta}-helices into trimers.  Proceedings 
of the National Academy of Sciences of the United States of America  
101:8342-8347. 
 
41.     Wille, H., M. D. Michelitsch, V. Guenebaut, S. Supattapone, D. J. Segel, D. 
Walther, H. Serban, S. Doniach, F. E. Cohen, D. A. Agard, and S. B. Prusiner. 
2002. Structural studies of the scrapie prion protein by electron 
crystallography. Biophysical Journal 82:825. 
 
42.     Wopfner, F., G. Weidenhofer, R. Schneider, A. von Brunn, S. Gilch, T. F. 
Schwarz, T. Werner, and M. Schatzl. 1999. Analysis of 27 mammalian and 9 
avian PrPs reveals high conservation of flexible regions of the prion protein. 
Journal of Molecular Biology 289:1163-1178. 
 
43.     Zscherp, C., H. Aygun, J. W. Engels, and W. Mantele. 2003. Effect of proline 
to alanine mutation on the thermal stability of the all-[beta]-sheet protein 
tendamistat. Biochimica et Biophysica Acta (BBA) - proteins & proteomics 
1651:139-145. 
 
44.     Nathaniel, C., L. A. Wallace, J. Burke, and H. W. DIRR. 2003. The role of an 
evolutionarily conserved cis-proline in the thioredoxin-like domain of human 
class Alpha glutathione transferase A1-1. Biochemical Journal 372:241-246. 
 
45.     Cordes, F. S., J. N. Bright, and M. S. P. Sansom. 2002. proline-induced 
Distortions of Transmembrane Helices. Journal of Molecular Biology 
323:951-960. 
 
 
 
 
PDB ID Species 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 
1QLX Human Y P N Q V Y Y R P M D E Y S N 
1AG2 Mouse Y P N Q V Y Y R P V D Q Y S N 
1B10 Hamster Y P N Q V Y Y R P V D Q Y N N 
1DWY Bovine Y P N Q V Y Y R P V D Q Y S N 
1UW3 Sheep Y P N Q V Y Y R P V D R Y S N 
1XYJ Cat Y P N Q V Y Y R P V D Q Y S N 
1XYQ Pig Y P N Q V Y Y R P V D Q Y S N 
1XYW Elk Y P N Q V Y Y R P V D Q Y N N 
1XYK Dog Y P N Q V Y Y R P V D Q Y N N 
1XU0 Frog M P N R V - Y R P M Y R G E E 
1U3M Chicken Y P N R V Y Y R D Y S S - - P 
1U5L Turtle Y P N R V Y Y K E Y N D R - S 
 
Table 1: Amino acid sequence alignment of the fragment 158–173 for the 
different species. The table shows NMR determined structures deposited in the 
PDB . It uses human sequence numbering with flanking proline residues 
underlined and β-sheet assigned structure consisting of amino acid residues 
VYY is highlighted in a continuous grey box. 
 
 
 
Variant 1QLX PPV PVV PVP VPP VVP VPV VVV 
Res 135 P P P P V V V V 
Res 158 P P V V P V P V 
Res 165 P V V P P P V V 
 
 
Table 2: Variants of proline/Val construct used in the MD simulations 
 
 
FIGURE LEGENDS 
 
Figure 1: Ribbon diagram of  S1, S2 and H1 with proline indicated by its ring. 
The diagram shows only S1, S2 and H1 with H2 and H3 omitted for clarity. The 
secondary structures are presented with helices and sheets. 
Figure 2: RMS deviations of all proline variants as a function of time for all 
proline variants. 
Figure 3: RMS fluctuations of all proline variants with residues numbered 
according to human prion residue sequence; blue bars denote α-helices, red bars 
β-sheets in wildtype structure; S1, sheet 1; S2, sheet 2; H1, helix 1; H2, helix 2; 
H3, helix 3 and black arrows indicate position of proline residues in the protein 
sequence. 
Figure 4: The number of residues forming β-sheets as a function of simulation 
time determined with DSSP during the simulation (a) VVV (b) VPV (c) PVV 
(d) PPV (e) PVP (f) VVP (g) PPP (h) VPP 
Figure 5: Secondary structure of variants as a function of simulation time 
determined by DSSP. The diagram shows (a) VVV (b) VVP(c) VPV (d) PVV 
variants. H1, H2 and H3 denote Helices 1, 2 and 3. S1 and S2 denote Sheet 1 
and Sheet 2. The colour guide denotes types of secondary structure.   
Figure 6: Secondary structure of variants as a function of simulation time 
determined with DSSP The diagram shows (a) VPP (b) PVP (c) PPV (d) PPP 
variants. H1, H2 and H3 denote Helices 1, 2 and 3. S1 and S2 denote Sheet 1 
and Sheet 2. The colour guide denotes types of secondary structure.   
Figure 7: Schematic diagram of the direction of the β-sheet expansion. The 
diagram shows the schematic of β-sheet expansion of all proline variants. The 
anti-parallel β-sheets are denoted by a pair of black boxes, the direction of the 
polypeptide denoted by black arrow, the presence and direction of expansion in 
grey arrows. 
Figure 8: Secondary structure as a function of simulation time determined with 
DSSP during the simulation (a) PVV (b) PPP (c) 1U3M (d) VVV; S1, sheet 1; 
S2, sheet 2; H1, helix 1; H2, helix 2; H3, helix 3. The color guide designates 
types of secondary structure. 
Figure 9: The number of residues forming β-sheets as a function of simulation 
time determined with DSSP during the simulation (a) PVV (b) PPP (c) 1U3M 
(d) VVV  
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